The investigators will compare the effects of PSGB(percutaneous stellate ganglion block) in patients with recurrent sustained VT/VF in spite of appropriate medical therapy and cardio-version/ defibrillation after correction of underlying correctable factors with those without PSGB by prospective randomized trail. PSGB will be performed every 3 days by anesthesiology specialist after cardiologist's request, until the stabilization of VT/VF. We will compare the frequency and episode number of VT/VF, procedure related complication, acute and long-term mortality.
Recurrent ventricular tachycardia(VT)/ fibrillation(VF) increases mortality, especially in patients with structural heart disease. It has been reported that cardiac sympathectomy reduces VT/VF episodes in patients with complex VT, long QT syndrome, catecholaminergic polymorphic VT, or myocarditis. However, cardiac sympathectomy operation is hard to conduct in patients with hemodynamically unstable recurrent VT/VF or electrical storm. Therefore, we hypothesized that bed-side percutaneous stellate ganglion block (PSGB) reduces VT/VF episodes and mortality in patients with repetitive VT/VF who are properly managed with optimal medical therapies.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
20
Antiarrhythmic drug
percutaneous stellate ganglion block (PSGB)
Severance Cardiovascular Hospital, Yonsei University Health System
Seoul, South Korea
Number of VT/VF episodes after randomization
Time frame: 5 days after randomization
Duration of VT/VF episodes after randomization
Time frame: 5 days after randomization
mortality
death, cause of death,
Time frame: 1 month after the enrollment
procedure related complication
Time frame: 1 month after the enrollment
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.